Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
IntroductionThere have been major changes in the classification and treatment of patients with idiopathic inflammatory myositis (IIM) in the last 2 decades. A major challenge is to identify the parameters that can affect the outcome and prognosis of these patients. Here, we have longitudinally followed a well‐characterized cohort of IIM patients in a rheumatology center and reported the outcome using the validated tools.MethodPatients with a clinical diagnosis of IIM and a follow‐up duration of greater than 2 years were prospectively included in the study. The duration of the study was 6 years: July 2016–July 2022. Clinical details and follow‐up were recorded using pro‐formas and outcomes were noted using validated tools. Ethics approval and written informed consent were taken.ResultsForty patients had a clinical diagnosis of IIM. Mean follow‐up duration was 43.8 (15) months. Out of 40 patients, 32 (80%) achieved remission (8 patients each were off corticosteroid and off treatment for >6 months), 5 (12%) expired and 3 (8%) had active disease. Disease course was non‐relapsing in 22/35 (73%) patients. Mean manual muscle testing‐8 score (n = 29) and myositis disease activity assessment tool score (n = 35) at the final visit were 75.6 (6.8) and 0.048 (0.07) respectively. Thirteen patients had damage (37%). Patients with disease duration >1 year at the time of presentation were more likely to develop chronic‐continuous disease course (P = .023, odds ratio [OR] = 7.6), more frequently required second‐line or third‐line immunosuppression (P = .001, OR = 24) with higher myositis damage index score (p = .0002, OR = 47).ConclusionsIIM patients had good outcomes with the majority achieving remission and near‐complete muscle recovery. However, the patients presenting late to the rheumatologists were more likely to have smoldering disease, more immunosuppressive medicines, and greater accumulated damage.
IntroductionThere have been major changes in the classification and treatment of patients with idiopathic inflammatory myositis (IIM) in the last 2 decades. A major challenge is to identify the parameters that can affect the outcome and prognosis of these patients. Here, we have longitudinally followed a well‐characterized cohort of IIM patients in a rheumatology center and reported the outcome using the validated tools.MethodPatients with a clinical diagnosis of IIM and a follow‐up duration of greater than 2 years were prospectively included in the study. The duration of the study was 6 years: July 2016–July 2022. Clinical details and follow‐up were recorded using pro‐formas and outcomes were noted using validated tools. Ethics approval and written informed consent were taken.ResultsForty patients had a clinical diagnosis of IIM. Mean follow‐up duration was 43.8 (15) months. Out of 40 patients, 32 (80%) achieved remission (8 patients each were off corticosteroid and off treatment for >6 months), 5 (12%) expired and 3 (8%) had active disease. Disease course was non‐relapsing in 22/35 (73%) patients. Mean manual muscle testing‐8 score (n = 29) and myositis disease activity assessment tool score (n = 35) at the final visit were 75.6 (6.8) and 0.048 (0.07) respectively. Thirteen patients had damage (37%). Patients with disease duration >1 year at the time of presentation were more likely to develop chronic‐continuous disease course (P = .023, odds ratio [OR] = 7.6), more frequently required second‐line or third‐line immunosuppression (P = .001, OR = 24) with higher myositis damage index score (p = .0002, OR = 47).ConclusionsIIM patients had good outcomes with the majority achieving remission and near‐complete muscle recovery. However, the patients presenting late to the rheumatologists were more likely to have smoldering disease, more immunosuppressive medicines, and greater accumulated damage.
Background: Connective tissue diseases (CTDs) are chronic in nature and carry a high risk of morbidity, disability, and mortality if not recognized and treated promptly. Data on clinical spectrum of CTDs in the pediatric age group are sparse from developing countries such as India. Objective: To study the clinicoepidemiological spectrum of CTDs in the pediatric age group. Methodology: A hospital-based, cross-sectional, observational study was undertaken over a period of 16 months from January 2021 to June 2022 in the dermatology outpatient department and pediatric rheumatology clinic in a tertiary care hospital in North India. Clinical and laboratory findings were recorded. Results: A total of 100 children diagnosed with a CTD were included in the study. The mean age was 11.11 ± 4.20 years. Out of 100 children, 55% were female and 45% were male with a male-to-female ratio of 1:1.2. Our study included 63% juvenile idiopathic arthritis, 17% systemic lupus erythematosus, 7% juvenile dermatomyositis, 6% Kawasaki disease, 3% systemic sclerosis, and 2% Henoch–Schonlein purpura and mixed CTD patients each. Mucocutaneous features commonly seen were rash (40%), oral ulcers (22%), and photosensitivity (18%). Commonly seen systemic features were joint pain (77%), followed by fever (63%). Conclusion: Mucocutaneous manifestations are frequently seen in CTDs and constitute a frequent and an early manifestation of CTD. Early recognition of CTD in the pediatric age group will help in timely initiation of treatment to prevent disabilities and mortality.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.